TWI789724B - 粒線體用於治療及/或預防肌腱受損或其相關疾病之用途 - Google Patents

粒線體用於治療及/或預防肌腱受損或其相關疾病之用途 Download PDF

Info

Publication number
TWI789724B
TWI789724B TW110109767A TW110109767A TWI789724B TW I789724 B TWI789724 B TW I789724B TW 110109767 A TW110109767 A TW 110109767A TW 110109767 A TW110109767 A TW 110109767A TW I789724 B TWI789724 B TW I789724B
Authority
TW
Taiwan
Prior art keywords
tendon
mitochondria
damage
prp
cells
Prior art date
Application number
TW110109767A
Other languages
English (en)
Chinese (zh)
Other versions
TW202135838A (zh
Inventor
鄭漢中
許智凱
曾惠卿
鄭安玲
Original Assignee
台灣粒線體應用技術股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 台灣粒線體應用技術股份有限公司 filed Critical 台灣粒線體應用技術股份有限公司
Publication of TW202135838A publication Critical patent/TW202135838A/zh
Application granted granted Critical
Publication of TWI789724B publication Critical patent/TWI789724B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/029—Separating blood components present in distinct layers in a container, not otherwise provided for
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/115—Platelets, megakaryocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
TW110109767A 2020-03-20 2021-03-18 粒線體用於治療及/或預防肌腱受損或其相關疾病之用途 TWI789724B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062992546P 2020-03-20 2020-03-20
US62/992546 2020-03-20

Publications (2)

Publication Number Publication Date
TW202135838A TW202135838A (zh) 2021-10-01
TWI789724B true TWI789724B (zh) 2023-01-11

Family

ID=77768010

Family Applications (12)

Application Number Title Priority Date Filing Date
TW110109767A TWI789724B (zh) 2020-03-20 2021-03-18 粒線體用於治療及/或預防肌腱受損或其相關疾病之用途
TW110109766A TWI789723B (zh) 2020-03-20 2021-03-18 粒線體用於治療或/及預防腎臟損傷相關疾病之用途
TW110109765A TWI787761B (zh) 2020-03-20 2021-03-18 粒線體用於促進傷口修復及/或傷口癒合之用途
TW113125869A TWI908184B (zh) 2020-03-20 2021-03-18 含有粒線體之組合物及其用途
TW111140519A TWI827321B (zh) 2020-03-20 2021-03-18 含有粒線體之組合物及其用於作為膠原蛋白增生促進劑之用途
TW112139490A TWI857807B (zh) 2020-03-20 2021-03-18 含有粒線體之組合物及其用於作為皮膚纖維母細胞活性促進劑之用途
TW111141019A TWI860566B (zh) 2020-03-20 2021-03-19 含有粒線體的組合物修復軟骨損傷或改善退化性關節炎的用途
TW113134886A TW202504624A (zh) 2020-03-20 2021-03-19 含有粒線體的組合物及其改善關節疾病的用途
TW113121686A TWI853788B (zh) 2020-03-20 2021-03-19 改善發炎反應的組合物及其用途
TW110109873A TWI787763B (zh) 2020-03-20 2021-03-19 含有粒線體的組合物
TW110109872A TWI849298B (zh) 2020-03-20 2021-03-19 促進毛髮再生的富粒線體血漿、其製造方法及其用途
TW110109874A TWI796653B (zh) 2020-03-20 2021-03-19 細胞培養組合物及其用途

Family Applications After (11)

Application Number Title Priority Date Filing Date
TW110109766A TWI789723B (zh) 2020-03-20 2021-03-18 粒線體用於治療或/及預防腎臟損傷相關疾病之用途
TW110109765A TWI787761B (zh) 2020-03-20 2021-03-18 粒線體用於促進傷口修復及/或傷口癒合之用途
TW113125869A TWI908184B (zh) 2020-03-20 2021-03-18 含有粒線體之組合物及其用途
TW111140519A TWI827321B (zh) 2020-03-20 2021-03-18 含有粒線體之組合物及其用於作為膠原蛋白增生促進劑之用途
TW112139490A TWI857807B (zh) 2020-03-20 2021-03-18 含有粒線體之組合物及其用於作為皮膚纖維母細胞活性促進劑之用途
TW111141019A TWI860566B (zh) 2020-03-20 2021-03-19 含有粒線體的組合物修復軟骨損傷或改善退化性關節炎的用途
TW113134886A TW202504624A (zh) 2020-03-20 2021-03-19 含有粒線體的組合物及其改善關節疾病的用途
TW113121686A TWI853788B (zh) 2020-03-20 2021-03-19 改善發炎反應的組合物及其用途
TW110109873A TWI787763B (zh) 2020-03-20 2021-03-19 含有粒線體的組合物
TW110109872A TWI849298B (zh) 2020-03-20 2021-03-19 促進毛髮再生的富粒線體血漿、其製造方法及其用途
TW110109874A TWI796653B (zh) 2020-03-20 2021-03-19 細胞培養組合物及其用途

Country Status (6)

Country Link
US (6) US20230042445A1 (https=)
EP (2) EP4122474A4 (https=)
JP (2) JP7563782B2 (https=)
CN (16) CN118557602A (https=)
TW (12) TWI789724B (https=)
WO (6) WO2021185364A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI789724B (zh) * 2020-03-20 2023-01-11 台灣粒線體應用技術股份有限公司 粒線體用於治療及/或預防肌腱受損或其相關疾病之用途
US20250186498A1 (en) * 2022-05-16 2025-06-12 Taiwan Mitochondrion Applied Technology Co., Ltd. Composition for hearing loss mitigation and use thereof
CN116478920B (zh) * 2023-05-05 2025-03-25 重庆理工大学 一种离体线粒体的体外储存方法
CN117180312A (zh) * 2023-10-09 2023-12-08 上海市第六人民医院 iMSCs线粒体在制备治疗骨缺损的药物中的应用
CN117883479A (zh) * 2023-11-02 2024-04-16 上海市第六人民医院 人源线粒体在制备治疗跟腱损伤的药物中的应用
WO2025126112A1 (en) * 2023-12-12 2025-06-19 Cells For Cells S.A. Composition enriched in mitochondria isolated from umbilical cord mesenchymal stem cells, useful in osteoarthritis

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0202298B1 (en) * 1984-11-29 1992-07-15 Regents Of The University Of Minnesota Wound healing agents
US6100068A (en) * 1997-01-21 2000-08-08 Paik-Inje Memorial Institute For Biomedical Science Method of protein production using mitochondrial translation system
US5834418A (en) * 1996-03-20 1998-11-10 Theratechnologies, Inc. Process for the preparation of platelet growth factors extract
US7005274B1 (en) * 1999-09-15 2006-02-28 Migenix Corp. Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
BRPI0507349A (pt) * 2004-02-02 2007-04-17 Nestec Sa genes associados á osteoartrite canina e processos e composições relacionados
TW200817019A (en) * 2006-07-10 2008-04-16 Univ Columbia De novo formation and regeneration of vascularized tissue from tissue progenitor cells and vascular progenitor cells
WO2009002811A2 (en) * 2007-06-22 2008-12-31 Children's Medical Center Corporation Therapeutic platelet compositions and methods
US8734854B2 (en) * 2009-07-09 2014-05-27 Orogen Biosciences Inc. Process for removing growth factors from platelets
US20130022666A1 (en) * 2011-07-20 2013-01-24 Anna Brzezinska Methods and compositions for transfer of mitochondria into mammalian cells
EP2741757B1 (en) * 2011-09-11 2018-05-16 Minovia Therapeutics Ltd. Compositions of functional mitochondria and uses thereof
EP2591812A1 (en) * 2011-11-14 2013-05-15 University of Twente, Institute for Biomedical Technology and Technical Medicine (MIRA) A dextran-based tissuelette containing platelet-rich plasma lysate for cartilage repair
US20140024677A1 (en) * 2012-04-09 2014-01-23 Musc Foundation For Research Development Methods for inducing mitochondrial biogenesis
US10702556B2 (en) * 2012-05-16 2020-07-07 Minovia Therpautices Ltd. Compositions and methods for inducing angiogenesis
AU2013326861A1 (en) * 2012-10-04 2015-04-23 Genesys Research Institute Platelet compositions and uses thereof
CN105163750B (zh) * 2013-02-07 2022-07-15 李震义 长效人重组可溶性肿瘤坏死因子α受体在制备预防和治疗慢性肝病重症肝损伤药物中的用途
US20140271589A1 (en) * 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
ES2883580T3 (es) * 2013-03-21 2021-12-09 Collplant Ltd Composiciones que comprenden colágeno y PRP para la regeneración de tejidos y su método de producción
US20150064715A1 (en) * 2013-08-28 2015-03-05 Musc Foundation For Research Development Urinary biomarkers of renal and mitochondrial dysfunction
TW201509425A (zh) * 2013-09-13 2015-03-16 Taichung Hospital Ministry Of Health And Welfare 以血液製備修復傷口用醫藥組合物之方法
TWI672147B (zh) * 2014-09-10 2019-09-21 台灣粒線體應用技術股份有限公司 以外源性粒線體爲有效成份之組合物、其用途及修復細胞之方法
JP6441472B2 (ja) * 2014-09-30 2018-12-19 台灣粒線體應用技術股▲扮▼有限公司Ｔａｉｗａｎ Ｍｉｔｏｃｈｏｎｄｒｉｏｎ Ａｐｐｌｉｅｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．，Ｌｔｄ． 活性成分として外因性ミトコンドリアを含む組成物、ならびにその使用およびそのための細胞修復法
CN105520891B (zh) * 2014-09-30 2019-05-21 台湾粒线体应用技术股份有限公司 以外源性线粒体为有效成份的组合物、其用途及修复细胞的方法
CN107249600A (zh) * 2014-12-31 2017-10-13 台湾粒线体应用技术股份有限公司 新颖医药组合物及其用于治疗肺损伤的用途
WO2016114781A1 (en) * 2015-01-15 2016-07-21 Boss William K Jr Repair and rejuvenation of tissues using platelet-rich plasma
CN104546915B (zh) * 2015-02-16 2018-12-11 天晴干细胞股份有限公司 一种治疗骨性关节炎的组合物的制备方法
IL299482B2 (en) * 2015-02-26 2025-02-01 Minovia Therapeutics Ltd Mammalian cells are enriched with active mitochondria
CA2987271A1 (en) * 2015-05-22 2016-12-01 President And Fellows Of Harvard College Methods, systems, and compositions for determining blood clot formation, and uses thereof
CN105030647B (zh) * 2015-09-14 2018-04-24 广州赛莱拉干细胞科技股份有限公司 一种减少皱纹的制剂及其制备方法
US20180303970A1 (en) * 2015-11-02 2018-10-25 VeriGraft AB Compositions and methods for healing wounds
US11903974B2 (en) * 2015-11-30 2024-02-20 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from cultured cells
CN105477018A (zh) * 2015-12-07 2016-04-13 深圳爱生再生医学科技有限公司 修复皮肤溃疡的干细胞制剂及其制备方法
SI4272834T1 (sl) * 2016-01-15 2026-03-31 Beth Israel Deaconess Medical Center, Inc. Terapevtska uporaba mitohondrijev in kombiniranih mitohondrijskih sredstev
US20170224764A1 (en) * 2016-02-10 2017-08-10 Cornell University Therapeutic targeting of mitochondria to prevent osteoarthritis
TWI637748B (zh) * 2016-07-12 2018-10-11 中山醫學大學 蓮蓬萃取物用於治療及／或預防腎臟病變之用途
CN106190963A (zh) * 2016-07-13 2016-12-07 浙江大学 一种采用线粒体移植促进损伤神经元存活的方法
EP3549589A4 (en) * 2016-11-30 2020-07-15 Paean Biotechnology Inc. PHARMACEUTICAL COMPOSITION CONTAINING MITOCHONDRIA
CN106822183B (zh) * 2016-12-26 2020-04-14 中山光禾医疗科技有限公司 一种光敏富血小板血浆凝胶及其制备方法和用途
US20200023005A1 (en) * 2017-03-26 2020-01-23 Minovia Therapeutics Ltd. Mitochondrial compositions and methods for treatment of skin and hair
US20200268940A1 (en) * 2017-05-15 2020-08-27 Richard J. Miron Liquid platelet-rich fibrin as a carrier system for biomaterials and biomolecules
EP3630134B8 (en) * 2017-06-01 2022-01-19 The United States of America as represented by The Secretary Department of Health and Human Services Formation of stable cartilage
US20190008896A1 (en) * 2017-07-07 2019-01-10 Richard Postrel Methods and Systems for the Prevention, Treatment and Management of Disease and Effects of Aging Via Cell-to-Cell Restoration Therapy Using Subcellular Transactions
CN107625969A (zh) * 2017-10-18 2018-01-26 南京市儿童医院 MiR‑214拮抗剂在制备用于减轻蛋白尿引起的肾小管损伤相关病症的药物中的用途
WO2019083201A2 (ko) * 2017-10-24 2019-05-02 주식회사 엑소코바이오 지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 신장 기능 개선 용도
KR20190052266A (ko) * 2017-11-08 2019-05-16 원광대학교산학협력단 우르솔산을 유효성분으로 포함하는 신장 기능의 개선 또는 치료용 조성물
KR102275822B1 (ko) * 2018-02-02 2021-07-12 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 류마티스 관절염 예방 또는 치료용 약학 조성물
CN112154210A (zh) * 2018-03-13 2020-12-29 利兰斯坦福初级大学董事会 用于逆转细胞老化的瞬时细胞重编程
WO2019183042A1 (en) * 2018-03-20 2019-09-26 Unity Biotechnology, Inc. Autologous mitochondrial extraction and expansion
US12329781B2 (en) * 2018-07-22 2025-06-17 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of renal diseases
CN112601532A (zh) * 2018-07-22 2021-04-02 米诺维亚疗法有限公司 使用富集有功能性线粒体的干细胞的线粒体增强疗法
US12268714B2 (en) * 2018-09-14 2025-04-08 Luca Science Inc. Transplantation of mitochondria into lymphoid organ and composition therefor
KR102128003B1 (ko) * 2018-10-31 2020-06-29 차의과학대학교 산학협력단 분리된 미토콘드리아를 포함하는 건병증 예방 또는 치료용 약학 조성물
CN110055216A (zh) * 2019-05-09 2019-07-26 张秀明 一种改善间质干细胞生物学功能的方法
CN110638833A (zh) * 2019-11-15 2020-01-03 西安圣德生物科技有限公司 促进毛发生长的组合物及其使用方法
CN110812480B (zh) * 2019-11-28 2021-04-02 中国科学院昆明动物研究所 一种抗菌肽和线粒体dna复合物及其多克隆抗体和应用
TWI789724B (zh) * 2020-03-20 2023-01-11 台灣粒線體應用技術股份有限公司 粒線體用於治療及/或預防肌腱受損或其相關疾病之用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
網路文獻 2014-12-23公開之「何謂PRP療法(自體血小板免疫血清回輸療法)」

Also Published As

Publication number Publication date
CN118252850A (zh) 2024-06-28
US20230023438A1 (en) 2023-01-26
US20230137870A1 (en) 2023-05-04
CN115103683A (zh) 2022-09-23
TW202308668A (zh) 2023-03-01
TWI789723B (zh) 2023-01-11
WO2021185340A1 (zh) 2021-09-23
WO2021185364A1 (zh) 2021-09-23
EP4122474A1 (en) 2023-01-25
CN117379458A (zh) 2024-01-12
JP2023518083A (ja) 2023-04-27
US20230023218A1 (en) 2023-01-26
CN115297872B (zh) 2024-03-29
CN115315248A (zh) 2022-11-08
JP7563782B2 (ja) 2024-10-08
TWI849298B (zh) 2024-07-21
TW202135779A (zh) 2021-10-01
CN115335065A (zh) 2022-11-11
WO2021185376A1 (zh) 2021-09-23
CN115315265A (zh) 2022-11-08
CN115315265B (zh) 2024-05-31
TW202504624A (zh) 2025-02-01
CN118319950A (zh) 2024-07-12
TW202135837A (zh) 2021-10-01
CN115135328A (zh) 2022-09-30
TW202135838A (zh) 2021-10-01
EP4122444A1 (en) 2023-01-25
TWI908184B (zh) 2025-12-11
JP2024133717A (ja) 2024-10-02
TW202442248A (zh) 2024-11-01
TWI796653B (zh) 2023-03-21
US20230165899A1 (en) 2023-06-01
WO2021185341A1 (zh) 2021-09-23
TWI827321B (zh) 2023-12-21
CN118236473A (zh) 2024-06-25
TW202438034A (zh) 2024-10-01
TW202135836A (zh) 2021-10-01
CN118557602A (zh) 2024-08-30
WO2021185377A1 (zh) 2021-09-23
CN118557604A (zh) 2024-08-30
US20230042445A1 (en) 2023-02-09
TW202404618A (zh) 2024-02-01
CN115103683B (zh) 2024-04-09
CN118557603A (zh) 2024-08-30
WO2021185342A1 (zh) 2021-09-23
EP4122444A4 (en) 2024-04-17
TWI860566B (zh) 2024-11-01
TW202135839A (zh) 2021-10-01
TWI787761B (zh) 2022-12-21
TW202200781A (zh) 2022-01-01
CN115135328B (zh) 2024-01-02
CN115297872A (zh) 2022-11-04
TWI787763B (zh) 2022-12-21
TWI857807B (zh) 2024-10-01
US20230016499A1 (en) 2023-01-19
CN118319951A (zh) 2024-07-12
JP7736347B2 (ja) 2025-09-09
TWI853788B (zh) 2024-08-21
EP4122474A4 (en) 2024-05-01
CN117357559A (zh) 2024-01-09
CN119876009A (zh) 2025-04-25
TW202306576A (zh) 2023-02-16

Similar Documents

Publication Publication Date Title
TWI789724B (zh) 粒線體用於治療及/或預防肌腱受損或其相關疾病之用途
Renzi et al. Autologous bone marrow mesenchymal stromal cells for regeneration of injured equine ligaments and tendons: a clinical report
Mohammadi et al. Effects of undifferentiated cultured omental adipose-derived stem cells on peripheral nerve regeneration
Palumbo Piccionello et al. Adipose micro-grafts enhance tendinopathy healing in ovine model: An in vivo experimental perspective study
Stefanis et al. Stromal vascular fraction and its role in the management of alopecia: a review
US20120177619A1 (en) Composition comprising a haematic component and its use for the treatment of degenerative joint disease
Wang et al. Mesenchymal stem cells from a hypoxic culture improve nerve regeneration
Stessuk et al. A topical cell therapy approach for diabetic chronic ulcers: Effects of mesenchymal stromal cells associated with platelet‐rich plasma
Liao et al. Platelet lysate promotes proliferation and angiogenic activity of dental pulp stem cells via store-operated Ca2+ entry
KR101816964B1 (ko) 피부 또는 혈관조직 손상 치료 보조용 약학 조성물
CN110856752A (zh) 一种自体脂肪干细胞+prp治疗骨性关节炎的实验方法
CN108324992A (zh) 软骨修复用组合物及关节软骨的修复方法
CN115025121B (zh) 一种复合细胞制剂及其制备方法与应用
Jiang et al. The effect of exosomes from canine bone mesenchymal stem cells on IL-1β-mediated inflammatory responses in chondrocytes
CN116059246A (zh) MSCs和AMP在制备干预特应性皮炎产品中的应用和制剂
Higginbotham Fat, fibroblasts, and fibrosis: how deposits of adipose tissue ameliorate dermal scarring
Kar et al. Stem cell approaches for tendon repair: delusion or insight
Boone Intra-articular administration of allogeneic equine bone marrow derived mesenchymal stem cells
Fayazi Intersection of Mechanobiology and Musculoskeletal Regenerative Rehabilitation
US20250161371A1 (en) Regenerative helminth containing compositions and uses thereof
Taguchi Regenerative Medicine for Tendon/Ligament Injuries: De Novo Equine Tendon/Ligament Neotissue Generation and Application
RU2679446C2 (ru) Способ лечения синдрома диабетической стопы
Purita of Regenerative Medicine
Bakowski et al. Intra-Articular Injections of Autologous Adipose Tissue or Platelet-Rich Plasma Comparably Improve Clinical and Functional Outcomes in Patients with Knee Osteoarthritis. Biomedicines 2022, 10, 684
이민지 Allogeneic Pure Platelet Rich Plasma Therapy for Adhesive Capsulitis